LAVAL, Québec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) (“Crescita” or the “Company”) is pleased to announce that holders of the issued and outstanding common shares (the “Shares”) of the Company (each a “Shareholder”) will be entitled to receive $0.80 per Share (subject to any applicable withholdings) (the “Consideration”) under its previously announced plan of arrangement (the “Arrangement”) with ClinActiv Holdings Inc. (“ClinActiv”) and its wholly-owned subsidiary (the “Purchaser”), pursuant to which the Purchaser will acquire all the Shares in exchange for all-cash consideration, subject to the terms and conditions of the arrangement agreement dated March 14, 2026 (the “Arrangement Agreement”).
The Company expects the Arrangement to be completed on June 3, 2026, subject to the satisfaction or waiver of all conditions to the Arrangement. Upon closing of the Arrangement, it is expected that the Shares will be delisted from the Toronto Stock Exchange (“TSX”) and that the Company will apply to the applicable Canadian securities regulators to cease to be a reporting issuer under applicable Canadian securities laws.
To receive the Consideration under the Arrangement, each registered Shareholder must complete, sign and deliver to TSX Trust Company, as depositary under the Arrangement, the letter of transmittal that accompanied the Company’s management information circular dated April 10, 2026, together with any other documents required thereby. Non-registered shareholders of the Company must contact the intermediary in whose name their Shares are registered for instructions and assistance in receiving the Consideration in respect of their Shares.
About Crescita
Crescita (TSX:CTX and OTC US: CRRTF) is a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and manufacturing capabilities. The Company offers a portfolio of high-quality, science-based non-prescription skincare products and a commercial stage prescription product, Pliaglis®. We also own multiple proprietary transdermal delivery platforms that support the development of patented formulations to facilitate the delivery of active ingredients into or through the skin. For more information, visit www.crescitatherapeutics.com.
About ClinActiv
ClinActiv is a global dermatology and consumer health platform focused on building science-driven products and businesses. Through cross-border collaboration, strategic partnerships and targeted acquisitions, ClinActiv aims to develop and scale differentiated products and platforms across North America, China, Europe and other global markets.
Forward-Looking Statements
Certain information set forth in this news release including, without limitation, management’s expectations with respect to: the completion of the Arrangement and the timing thereof; the satisfaction of the conditions to closing; the delisting of the Shares from the TSX and the Company’s intention to cease to be a reporting issuer, is forward-looking information within the meaning of applicable securities laws. Forward-looking information may in some cases be identified by words such as “may”, “will”, “anticipates”, “expects”, “intends” and similar expressions referencing future events or future performance.
Forward-looking information is, by its nature, subject to numerous risks and uncertainties, some of which are beyond the Company’s control. The forward-looking information contained in this news release is based on certain expectations and assumptions made by the Company, including expectations and assumptions concerning the satisfaction of the conditions to closing, the delisting of Shares from the TSX and the submission of the application to cease to be a reporting issuer following the delisting of the Shares.
Forward-looking information is subject to various risks and uncertainties which could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include, but are not limited to: general global economic, market and business conditions; failure to satisfy the conditions to the completion of the Arrangement; diversion of management time on the Arrangement; the possibility that the Arrangement Agreement may be terminated in certain circumstances; and other factors, many of which are beyond the control of the Company. The anticipated timeline for completion of the Arrangement may change for a number of reasons, including the need for additional time to satisfy the conditions to the completion of the Arrangement. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release concerning the timing of the Arrangement or whether the Arrangement will be completed. A comprehensive discussion of other risks that impact the Company is included in the Company’s most recent Annual Information Form dated March 30, 2026, under the heading “Risk Factors”, and are described from time to time in the reports and disclosure documents filed by the Company with Canadian securities regulatory agencies and commissions which are available under Crescita’s profile at www.sedarplus.ca.
Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Crescita does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
Contacts
Linda Kisa, CPA, CA
Vice-President, Corporate Affairs and Secretary
Email: lkisa@crescitatx.com
